home / stock / crdf / crdf articles
Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected thir...
- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIR...
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibi...
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 152.8% to $1.09. The company announced the effective date for its reverse stock split after ...
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares rose 69.9% to $0.7391 in pre-market trading. The company announced the effective date for its revers...
Cardiff Oncology, Inc. (NASDAQ: CRDF) shares are trading higher Tuesday after-hours after the company announced clinical data in pancreatic cancer ...
News, Short Squeeze, Breakout and More Instantly...
Cardiff Oncology Inc. Company Name:
CRDF Stock Symbol:
NASDAQ Market:
Cardiff Oncology Inc. Website:
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in M...
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR dem...